Syntax Bio
1 known investors
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.
BiotechDeep TechMedical Devices
Investors · 1
In the news
- Syntax Bio expands Series A to $14.4M, inks Mayo Clinic collaboration - Chicago Business Journalbizjournals.com · 2026
- Syntax Bio Raises $14.4 Million Series A And Announces Leadership Appointmentspulse2.com · 2026
- Syntax Bio Raises $14.4M for CRISPR Cell Therapyallsci.com · 2026
- Syntax Bio expands funding round to $14.4M, reshuffles leadership team - Crain's Chicago Businesschicagobusiness.com · 2026
- Syntax Bio expands Series A to $14.4M, adds leadership and board members (IBB:NASDAQ) | Seeking Alphaseekingalpha.com · 2026
- Syntax Bio Announces Expanded Series A and Leadership Appointmentsfinance.yahoo.com · 2026